(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Jazz Pharmaceuticals's revenue in 2026 is $4,718,126,000.On average, 25 Wall Street analysts forecast JAZZ's revenue for 2026 to be $314,718,921,956, with the lowest JAZZ revenue forecast at $298,800,037,060, and the highest JAZZ revenue forecast at $326,914,841,836. On average, 25 Wall Street analysts forecast JAZZ's revenue for 2027 to be $330,509,428,748, with the lowest JAZZ revenue forecast at $297,002,743,604, and the highest JAZZ revenue forecast at $385,904,580,624.
In 2028, JAZZ is forecast to generate $355,478,969,976 in revenue, with the lowest revenue forecast at $312,408,116,084 and the highest revenue forecast at $393,093,754,448.